CER-001

06/01/2017 - "Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001. "
06/01/2017 - "Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. "
06/01/2017 - "Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. "
02/01/2017 - "The CARAT is a phase 2, multicenter trial in which 292 patients with an ACS undergoing intracoronary ultrasonography and showing percent atheroma volume (PAV) greater than 30% are randomly assigned to treatment with ten infusions of CER-001 3 mg/kg or matching placebo, administered at weekly intervals. "
01/01/2016 - "HDL mimetic CER-001 targets atherosclerotic plaques in patients."

01/01/2021 - "CER-001 is an HDL mimetic that has been tested in different pathological conditions, but never with LCAT deficiency. "
01/01/2021 - "Treatment with CER-001 ameliorates the dyslipidemia typically associated with LCAT deficiency and more importantly limits renal damage in a mouse model of renal disease in LCAT deficiency. "
01/01/2021 - "This study was designed to investigate whether the absence of LCAT affects the catabolic fate of CER-001, and to evaluate the effects of CER-001 on kidney disease associated with LCAT deficiency. "
01/01/2021 - "Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithin-Cholesterol Acyltransferase Deficiency."
01/01/2021 - "CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency."

01/01/2022 - "CER-001 was tested in an FLD patient with dramatic kidney disease for 12 weeks. "
01/01/2021 - "This study was designed to investigate whether the absence of LCAT affects the catabolic fate of CER-001, and to evaluate the effects of CER-001 on kidney disease associated with LCAT deficiency. "
01/01/2021 - "CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency."

05/01/2015 - "In the present study, we evaluated the effect of serial infusions with CER-001, a recombinant human apolipoprotein A-I (apoA-I)-containing high-density lipoprotein-mimetic particle, on carotid artery wall dimensions in patients with HoFH. "
05/01/2015 - "In HoFH, 12 biweekly infusions with an apoA-I-containing high-density lipoprotein-mimetic particle resulted in a significant reduction in carotid mean vessel wall area, implying that CER-001 may reverse atherogenic changes in the arterial wall on top of maximal low-density lipoprotein-lowering therapy. "

01/01/2021 - "Treatment with CER-001 ameliorates the dyslipidemia typically associated with LCAT deficiency and more importantly limits renal damage in a mouse model of renal disease in LCAT deficiency. "